Claims for Patent: 9,683,985

Summary for Patent: 9,683,985

Title:	Methods for assessing and identifying or evolving conditionally active therapeutic proteins
Abstract:	Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.
Inventor(s):	Kodandapani; Lalitha (San Diego, CA), Bookbinder; Louis H. (San Diego, CA), Frost; Gregory I. (Del Mar, CA), Sheridan; Philip Lee (San Diego, CA), Shepard; Harold Michael (San Diego, CA), Wei; Ge (San Diego, CA), Huang; Lei (San Diego, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	13/200,666
Patent Claims:	1. An in vitro method for identifying/selecting a modified therapeutic protein that treats tumors and that has greater activity in a tumor microenvironment in a subject compared to a non-tumor environment in the subject, comprising: 1) testing the binding activity of a plurality of modified therapeutic anti-tumor proteins to the target of the therapeutic anti-tumor proteins under conditions a) and under conditions b), wherein: the modified therapeutic anti-tumor proteins are anti-tumor antibodies or antigen-binding portions thereof; the conditions in a) comprise low pH that is between 5.8 and 6.8, and human serum; the conditions in b) comprise pH that is between about 7.2 and 7.8, and human serum at the same concentration as in a); the serum concentration in both conditions is the same and is 15%-35% by volume; optionally, the conditions in a) compared to the conditions in b) comprise one or more properties in addition to lower pH selected from among hypoxia, higher lactate concentration and higher pyruvate concentration; all other conditions in a) and b) are the same; the activity tested is binding to a target protein of the therapeutic protein; each modified therapeutic protein contains an amino acid replacement, insertion, and/or deletion of an amino acid residue or residues compared to the unmodified form of the therapeutic protein; and each modified protein is tested in each of conditions a) and b); 2) comparing the binding activity of the modified therapeutic proteins in a) to the binding activity in b); and 3) selecting/identifying a modified therapeutic protein that has greater binding activity for the target protein in a) compared to b), thereby identifying a modified therapeutic antibody or antigen-binding portion thereof that is conditionally active such that it has greater binding activity in the low pH conditions of a tumor microenvironment compared to the pH conditions of a non-tumor environment. 2. The method of claim 1, wherein the conditions in b) comprise pH between about 7.2 to about 7.6. 3. The method of claim 1, wherein the pH in b) is the pH of a healthy tissue. 4. The method of claim 3, wherein the healthy tissue is the gastrointestinal (GI) tract, the skin, the vasculature, the blood or the extracellular matrix. 5. The method of claim 1, wherein the modified therapeutic proteins comprise an antigen-binding portion of an anti-tumor antibody. 6. The method of claim 1, wherein the therapeutic protein is selected from among Cetuximab, Trastuzumab, Rituximab, Bevacizumab, Alemtuzumab, Panitumumab, Ranibizumab, Ibritumomab, Ibritumomab tiuxetan, Tositumomab, I131Tositumomab, Catumaxomab, Gemtuzumab, Gemtuzumab ozogamicine, Abatacept, Belatacept, Ipilimumab, Tremelimumab, Volociximab, F200, MORAb-009, SS1P, Cixutumumab, Matuzumab, Nimotuzumab, Zalutumumab, Necitumumab IMC-11F8, mAb806/ch806, Sym004 and mAb-425. 7. The method of claim 1, wherein the modified therapeutic protein that is tested is an antibody that comprises one or more amino acid replacements in a complementarity determining region (CDR) compared to an unmodified form of the antibody. 8. The method of claim 1, wherein each modified therapeutic protein contains a single amino acid replacement or two, three, four, five, six, seven, eight, nine or more amino acid replacements compared to an unmodified form of the therapeutic protein. 9. The method of claim 1, wherein: a plurality of therapeutic proteins are modified to generate a collection of modified therapeutic proteins, wherein: each modified protein in the collection is tested in each of a) and b); each modified therapeutic protein in the collection contains a single amino acid replacement compared to an unmodified form of the therapeutic protein; in the collection, the amino acid at each modified position is replaced by up to 1-19 other amino acids other than the original amino acid at the position, whereby each modified therapeutic protein contains a different amino acid replacement; and in the collection, every amino acid along the length of the therapeutic protein, or a selected portion thereof, is replaced. 10. The method of claim 1, wherein: the modified therapeutic protein comprises an amino acid replacement; and histidine is a replacing amino acid and/or the histidines in the protein is/are replaced by a non-basic or uncharged amino acid. 11. The method of claim 1, wherein: the modified therapeutic protein comprises an amino acid replacement; and the amino acid replacement is replacement with an amino acid selected from among Arg, Asp, Glu, His and Lys. 12. The method of claim 1, wherein: the modified protein comprises an amino acid replacement; and the amino acid replacement is replacement with His. 13. The method of claim 1, wherein binding is assessed by an immunoassay. 14. The method of claim 13, wherein the immunoassay comprises an ELISA. 15. The method of claim 1, wherein the modified therapeutic protein is expressed on the surface of a cell. 16. The method of claim 15, wherein: the activity assessed is binding of the target protein to the modified therapeutic protein on the surface of the cell; the target protein is contacted with a population of the cells that each express different modified therapeutic proteins; and a cell or cells is/are identified that bind(s) to the target protein, thereby identifying a modified therapeutic protein that exhibits binding activity. 17. The method of claim 16, wherein the target protein is detectably labeled or can be detected. 18. The method of claim 17, wherein the target protein is fluorescently labeled or is detected by a secondary reagent that is fluorescently labeled. 19. The method of claim 17, wherein detecting or measuring the binding is by fluorescence activated cell sorting (FACS). 20. The method of claim 1, wherein the target protein is a receptor or a portion thereof that binds to a ligand. 21. The method of claim 20, wherein the target protein of the therapeutic protein is a receptor that is a tumor antigen. 22. The method of claim 21, wherein the target protein of the therapeutic protein is a member of the Her family of receptors. 23. The method of claim 22, wherein the target protein of the therapeutic protein is the EGFR receptor or the extracellular domain thereof. 24. The method of claim 1, wherein the activity in a) is greater than in b) by a ratio of at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50 or more. 25. The method of claim 1, further comprising repeating steps 1)-3) a plurality of times, wherein in each repetition, further modified proteins of a selected modified protein or proteins are generated and tested, whereby the therapeutic protein is evolved to exhibit increased activity at the lower pH in a). 26. The method of claim 1, wherein the therapeutic protein is an anti-EGFR antibody. 27. The method of claim 1, wherein: the conditions that exist in the tumor microenvironment a) compared to the non-tumor environment b) comprise one or more properties in addition to lower pH selected from among hypoxia, increased lactate concentration, increased pyruvate concentration, increased interstitial fluid pressure, and altered metabolites or metabolism indicative of a tumor compared to the non-tumor environment. 28. The method of claim 1, wherein the conditions in a) further comprise a lactate concentration that is 10 mM to 20 mM and/or the conditions in b) further comprise lactate concentration that is 0.5 to 5 mM. 29. The method of claim 1, wherein the conditions in a) further comprise elevated lactic acid concentration compared to the conditions in b). 30. The method of claim 1, wherein the concentration of human serum is 15% to 30% by volume, inclusive. 31. The method of claim 1, wherein the concentration of human serum is 15% to 25% by volume, inclusive. 32. The method of claim 1, wherein the conditions in a) further comprise a lactate concentration that is 10mM to 20 mM; and the conditions in b) further comprise lactate concentration that is 0.2 mM to 4 mM.

Details for Patent 9,683,985

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-09-08
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2030-09-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-09-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-09-08